ANTICOAGULANTS: NEW-GENERATION AGENTS AND THEIR ADVANTAGES
DOI:
https://doi.org/10.5281/zenodo.18655608Keywords:
Anticoagulants; new-generation anticoagulants; DOAC; NOAC; rivaroxaban; apixaban; dabigatran; edoxaban; venous thromboembolism; thrombosis; embolism; atrial fibrillation; hemorrhagic risk; reversal agents.Abstract
This article provides a comprehensive scientific analysis of current trends in anticoagulant therapy, with particular emphasis on the new-generation anticoagulants known as direct oral anticoagulants (DOACs/NOACs). The study highlights their clinical significance, pharmacological characteristics, and comparative advantages over conventional anticoagulants. Special attention is given to the role of anticoagulants in the prevention of thromboembolic complications, as well as to contemporary clinical approaches to their use in cardiovascular disorders and venous thromboembolism.
References
Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2009;361(12):1139–1151. Massachusetts Medical Society.
Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 2011;365(10):883–891. Massachusetts Medical Society.
Granger C.B., Alexander J.H., McMurray J.J.V. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2011;365(11):981–992. Massachusetts Medical Society.
Giugliano R.P., Ruff C.T., Braunwald E. et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2013;369(22):2093–2104. Massachusetts Medical Society.
Ruff C.T., Giugliano R.P., Braunwald E. et al. Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin. The Lancet. 2014;383(9921):955–962. Elsevier.
Kearon C., Akl E.A., Ornelas J. et al. Antithrombotic Therapy for VTE Disease. CHEST. 2016;149(2):315–352. American College of Chest Physicians.
January C.T., Wann L.S., Calkins H. et al. 2019 AHA/ACC/HRS Guideline for Atrial Fibrillation. Circulation. 2019;140(2):e125–e151. American Heart Association.
Hindricks G., Potpara T., Dagres N. et al. 2020 ESC Guidelines for Atrial Fibrillation. European Heart Journal. 2021;42(5):373–498. Oxford University Press.
Steffel J., Collins R., Antz M. et al. 2021 European Heart Rhythm Association Practical Guide on NOACs. Europace. 2021;23(10):1612–1676. Oxford University Press.
Schulman S., Kearon C. Definition of Major Bleeding in Clinical Investigations. Journal of Thrombosis and Haemostasis. 2005;3(4):692–694. Wiley-Blackwell.
Pollack C.V., Reilly P.A., van Ryn J. et al. Idarucizumab for Dabigatran Reversal. New England Journal of Medicine. 2015;373(6):511–520. Massachusetts Medical Society.
Connolly S.J., Crowther M., Eikelboom J.W. et al. Full Study Report of Andexanet Alfa for Bleeding. New England Journal of Medicine. 2019;380(14):1326–1335. Massachusetts Medical Society.
Brunton L.L., Hilal-Dandan R., Knollmann B.C. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. 2018. pp. 857–878. McGraw-Hill Education.
Katzung B.G. Basic & Clinical Pharmacology. 15th ed. 2021. pp. 605–622. McGraw-Hill Education.
O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. Tromboembolik kasalliklarning profilaktikasi va davolash bo‘yicha klinik protokollar. 2020. 45–78-bet. Toshkent: SSV nashriyoti.
